Abstract library

6 results for "Concas".
#942 Ileal Neuroendocrine Well-Differentiated Tumors: Prognostic factors with Focus on Loss of Succinate Dehydrogenase (SDHB) Expression
Introduction: Ileal Neuroendocrine Well-Differentiated Tumors (INWDT) are the most common neuroendocrine neoplasms in the gastrointestinal tract. Gene mutations of SDH complex drive pathogenesis of cancer cells through their role in angiogenesis and cell proliferation.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
#964 Ewing Sarcoma a Dangerous Pitfall for Poorly Differentiated Neuroendocrine Carcinoma (PDEC) in Ileum
Introduction: Ewing sarcoma (ES) primary to the ileum (IES) has rarely been documented, and shows close similarities in histology and clinical presentation with PDEC.EWSR1-FEV translocation is exceedingly rare in ES, as FEV expression is restricted to prostate, brain, and serotonin neuroendocrine cells (NE) and related tumors.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
#1446 Morphological Differentiation and Ki67-Index Are Predictive of Prognosis Independently of the Type of Therapy in Gastroenteropancreatic Neuroendocrine Carcinomas (NECs)
Introduction: Gastroenteropancreatic (GEP) neuroendocrine carcinomas (NECs) are considered an heterogeneous category.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: Ki-67, OS, PFS, NEC
#1725 Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial
Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Sara Pusceddu
Authors: Prinzi N, Femia D, Concas L, Lo Russo G, ...
Keywords: lanreotide, metformin
#1726 A Long-Term Complete Response (CR) of Avelumab in Patient (pt) with Advanced Merkel Cell Carcinoma (MCC)
Introduction: MCC is a rare and aggressive cutaneous neuroendocrine cancer linked to exposure to the Merkel Polyomavirus (MCPyV). Cisplatin and VP16 chemo may be an effective treatment for metastatic MCC, but responses are often transient. The blockade of programmed death 1 (PD-1) immune inhibitory pathway by avelumab, an anti-PD-L1 checkpoint inhibitor, is being investigated in solid neoplasms. This strategy can also be of interest in MCC because these tumors often express PD-L1
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD Sara Pusceddu
#1729 Outstanding Response to Sunitinib in a Patient with Unresectable Retroperitoneal Paraganglioma
Introduction: Pheochromocitomas and Paragangliomas (PCs/PGLs) are rare neuroendocrine tumors arising from the adrenal medulla and extra-adrenal ganglia. Around 30-40% of these neoplasms are genetically determined. PCs/PGLs arising from the sympathetic chain can synthesize bioactive amines leading to typical syndromes, in contrast to parasympathetic PGLs that are mainly non-secretory.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD Sara Pusceddu